{
  "docId": "019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "docSlug": "6ded4b1cfe2c",
  "documentTitle": "Bristol-Myers Squibb Company (BMY)",
  "authorId": "03_Starboard_Value",
  "authorName": "Starboard Value",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2019-03-18 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 74,
  "pageCount": 197,
  "prevPage": 73,
  "nextPage": 75,
  "slideType": "valuation_table",
  "function": "show_valuation_bridge",
  "density": "dense",
  "nDataPoints": 100,
  "notes": "Includes a waterfall-style bridge diagram showing the components of the BMY deal value.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "bullet_list",
    "data_table",
    "valuation_table",
    "process_diagram"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622b-71dc-a6d9-fc4318e06f9b/74",
  "deckHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b",
  "deckJsonHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b.json",
  "deckAnchorHref": "/decks/019dd923-622b-71dc-a6d9-fc4318e06f9b#slide-74",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.82,
        "y": 0.4
      },
      "kind": "callout",
      "text": "Bristol-Myers management assumptions on operating costs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23826e37-51c1-4aeb-acf9-7d2486cc7e4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.73,
        "y": 0.7
      },
      "kind": "callout",
      "text": "We understand how Bristol-Myers arrives at a ~$55 billion valuation for Celgene's marketed products",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b8ea405-cf55-44ea-8457-dd5edc83256a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "While we understand management's math, we believe there is still risk to these assumptions",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0f18-711c-9ae2-bf229090fc5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.36,
        "x": 0.49,
        "y": 0.65
      },
      "kind": "chart",
      "text": "BMY Management View of Celgene Deal Value",
      "attrs": null,
      "subkind": "waterfall-bridge",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee1e67ad-de12-4bea-9b25-70f6c0c99987",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "DCF Value: $55 billion",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-0f18-711c-9ae2-c2c3a764d7dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Bristol-Myers management communicated to us that they are assuming initial operating costs of $3.5 billion for marketed products, which will then scale down over time as the products go generic.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a764947d-8241-48a2-a5e6-271f59b48a42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.81,
        "x": 0.04,
        "y": 0.26
      },
      "kind": "table",
      "text": "Bristol-Myers Management Assumptions for Celgene's Marketed Products",
      "attrs": null,
      "subkind": "valuation",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e7094eb-cf1b-4b0a-92a1-d21377f9b01c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.92,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "title",
      "text": "While we understand management's math, we believe there is still risk to these assumptions",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2dfb8537-72d9-416f-831b-8d934a23fa17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "We Understand How Bristol-Myers Arrives at Its $55 Billion Valuation for Celgene's Marketed Products Business",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "870eed1c-27d3-4d06-af8a-d2d09058cd2e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall / value bridge",
      "slug": "waterfall-bridge",
      "agent": null,
      "layer": "slide",
      "matchId": "ed79fc59-f467-4e1a-ba18-d91b958d3abb",
      "evidence": "BMY Management View of Celgene Deal Value",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "valuation-bridge",
      "slug": null,
      "matchId": "18b76243-d9b9-470e-9850-0ced3d479cf0",
      "evidence": "Waterfall chart showing components of deal value",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 77,
      "from": 71,
      "name": "Iceberg",
      "slug": "10-iceberg",
      "bestFor": "Consulting, complex problem solving, organizational change",
      "matchId": "81bf725f-6cb1-4bc2-96ea-81ccf9b935e8",
      "evidence": "The document questions the valuation of Celgene's pipeline and the true cost of the acquisition.",
      "position": 1,
      "objective": "Exposing the true cost of the acquisition",
      "structure": "The Symptom (Visible) -> The System (Hidden) -> The Root Cause",
      "confidence": 0.7,
      "description": "Reveal that the visible problem is merely a symptom of a deeper root cause"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}